PureTech

PureTech is one of the...

• FTSE 350.

PureTech is a company listed under the stock ticker PRTC (US).

They are in:

• Biotechnology67%
• Healthcare33%

View the org chart displaying its 39 main executives

Most searched biographies at PureTech

• Bharatt Chowrira, Chief Executive Officer
• Sharon Barber-Lui, Director
• Kiran Mazumdar-Shaw, Director

Popular executive movements at PureTech

• Bharatt Chowrira, who was President and Chief Business, Finance and Operating Officer, is promoted to Chief Executive Officer  (posted on April 12 2024).
• Robert Lyne will join the company as Chief Portfolio Officer in Jan. 2024  (posted on September 27 2023).

Create your alert
to follow the executive moves at PureTech.

PureTech has 2,282 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
• Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
• Histogen has filed for bankruptcy protection  (posted on April 19 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion
• Vik Bajaj - Director at Interline Therapeutics

Learn more about the Biotechnology industry >

Press releases by PureTech

• Notice of Half-Yearly Results | PureTech Health
• PureTech Founded Entity Akili Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan | PureTech Health
• PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of AKL-T01 Product Candidate | PureTech Health
• PureTech Founded Entity Akili Announces Public Company Board of Director Nominees | PureTech Health
• PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 (Deupirfenidone) in IPF and Advances LYT-200 (Anti-Galectin-9 mAb) | PureTech Health
• PureTech Founded Entity Vedanta Biosciences Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia | PureTech Health
• PureTech News | PureTech Health
• PureTech Founded Entity Gelesis Announces Additional $15 Million Pre-Order for Plenity®, Bringing Total Pre-Paid Orders from Ro for Plenity to $55 Million | PureTech Health
• Results of Annual General Meeting | PureTech Health
• PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute "Long" COVID with Respiratory Complications | PureTech Health
• View more press releases Close

Social media about PureTech

• PureTech on Wikipedia, Google News & Yahoo Finance
• PureTech on LinkedIn, Twitter & YouTube

Contact by email its executives including Sharon Barber-Lui

Call PureTech at +1 617...

View the org chart

Register to receive your alert

Report an error